Efficacy analysis of three‑year subcutaneous SQ‑standardized specific immunotherapy in house dust mite‑allergic children with asthma

  • Authors:
    • Yu Hui
    • Ling Li
    • Jun Qian
    • Yun Guo
    • Xilian Zhang
    • Xiaojuan Zhang
  • View Affiliations

  • Published online on: January 2, 2014     https://doi.org/10.3892/etm.2014.1469
  • Pages: 630-634
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to evaluate the efficacy of three-year subcutaneous SQ‑standardized specific immunotherapy (SCIT) in house dust mite (HDM)-allergic children with asthma. Ninety children with allergic asthma to HDMs, with or without allergic rhinitis, were randomly divided into two groups, the treatment group and the control group. The treatment group received SCIT combined with standardized glucocorticoid management and the control group received standardized glucocorticoid management alone for a period of three years. The mean daily dose of inhaled corticosteroids (ICSs), a four‑week diary recording the symptom scores of asthma, peak expiratory flow (PEF) measurements, skin prick test results and serum immunoglobulin E (IgE) levels were assessed prior to treatment and following one, two and three years of treatment. The median dose of ICS was reduced in the treatment group after two and three years of treatment compared with that of the control group. After three years of treatment, the discontinuation percentage of ICS in the treatment group was higher than that in the control group. The treatment group demonstrated significantly reduced daytime and night‑time asthmatic symptom scores, increased PEF values and reduced serum IgE levels after two and three years of treatment compared with those in the control group (P﹤0.05). In conclusion, three‑year SCIT treatment combined with ICS is an effective immunotherapy for children with allergic asthma and resulted in a reduction of the required ICS dose.
View Figures
View References

Related Articles

Journal Cover

2014-March
Volume 7 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hui Y, Li L, Qian J, Guo Y, Zhang X and Zhang X: Efficacy analysis of three‑year subcutaneous SQ‑standardized specific immunotherapy in house dust mite‑allergic children with asthma. Exp Ther Med 7: 630-634, 2014
APA
Hui, Y., Li, L., Qian, J., Guo, Y., Zhang, X., & Zhang, X. (2014). Efficacy analysis of three‑year subcutaneous SQ‑standardized specific immunotherapy in house dust mite‑allergic children with asthma. Experimental and Therapeutic Medicine, 7, 630-634. https://doi.org/10.3892/etm.2014.1469
MLA
Hui, Y., Li, L., Qian, J., Guo, Y., Zhang, X., Zhang, X."Efficacy analysis of three‑year subcutaneous SQ‑standardized specific immunotherapy in house dust mite‑allergic children with asthma". Experimental and Therapeutic Medicine 7.3 (2014): 630-634.
Chicago
Hui, Y., Li, L., Qian, J., Guo, Y., Zhang, X., Zhang, X."Efficacy analysis of three‑year subcutaneous SQ‑standardized specific immunotherapy in house dust mite‑allergic children with asthma". Experimental and Therapeutic Medicine 7, no. 3 (2014): 630-634. https://doi.org/10.3892/etm.2014.1469